Field of expertise
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:
Genetic Toxicology
We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.
Reproductive Toxicology
By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.
Mechanistic Toxicology
All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).
Toxys in 90 seconds
This video gives you a quick insight into what Toxys could do for you.
Happy Customers
We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:
"The differentiation between aneugens and clastogens is important in the hazard assessment of our pharmaceutical compounds. ToxTracker ACE conveniently combines the relevant endpoints to be able to do this"
“As a modern safety laboratory requiring mechanistic insights into mammalian toxicology, we adopted ToxTracker and installed the assay in-house. The expertise, training and support provided by Toxys for the technology transfer were excellent resulting in a seamless set-up of the assay in our facilities. In addition, we have had terrific reactivity from Giel and his team with our questions.”
"The ToxTracker assay is an excellent tool to evaluate the genotoxic potential of compounds, generating great additional value by dissecting the underlying genotoxic mechanisms, and thereby better assess the relevance of the genotoxic response in a fast and cost-efficient manner.”
“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”
"Orion has worked successfully with Toxys on a couple of occasions. We are happy with the open communication which makes planning the experiments and interpreting the results easy and straightforward. The assay is excellent follow-up for our in-house micronucleus test to reveal the mode-of-action and hence validate or in-validate the borderline positive/negative dilemma."
“A succesful genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”
"Mechanism-based screening assays like the ToxTracker can make a valuable contribution to the routine safety compliance screening of our products"
“The expertise at Toxys is clear when you discuss results. The proactive team works hard to generate results within the timelines"
Toxys appoints Susan Swarte as new non-executive Board member
Leiden, The Netherlands. July 14, 2020 - Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industry. Today, Toxys...
Webinar: A highly quantitative in vitro method for mechanistic genotoxicity screening
On the 12th of May our recorded webinar with our partners at Miltenyi Biotech, introducing our in vitro genotoxicity assay, ToxTracker®, its opportunities, advantages and challenges faced when using this assay for mechanistic toxicity testing, was released. We also highlight the potential of using reliable flow...
Toxys signs agreement with BioPartner Leiden for new laboratory
Leiden, The Netherlands. May 5, 2020 - Toxys is an innovative Dutch biotech company that develops unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Today, Toxyssigned an agreement with BioPartner Leiden for its new laboratory facilities. In spring...
ToxTracker webinar with user applications now available!
On the 18th of March our webinar on ToxTracker, including use applications for the Fragrance and Flavour industry and Agro-Chemical industry has been held. During this webinar, our new assays, ReproTracker and TubulinTracker, were also launched. The webinar can be found at our dedicated website for all...
COVID19 Contingency Planning and Continuity of Project Delivery from Toxys
Toxys has been monitoring the global corona virus outbreak since the beginning of this year and is updating business continuity plans daily. We want to assure you that we remain dedicated to provide high quality services to our clients while also protecting the health of...
Toxys raises €2 million financing for global expansion of its unique animal-free chemical safety tests
Leiden, The Netherlands. March. 10, 2020 - Toxys is an innovative Dutch biotech company that develops unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Today, Toxys announces a €2 million funding round from KIKK Capital, InnovationQuarter, Zeeland Investment...
Save the date: Altertox/Toxys workshop Novel in vitro methods and AOP approaches in genetic toxicology
Hands-on workshop: Novel in vitro methods and AOP approaches in genetic toxicology. By: Altertox/Toxys When: 7-8 July 2020 Where: Leiden, The Netherlands Program will be available soon, please contact us for any questions. ...
ToxTracker event and launch party at SOT 2020
You are cordially invited to join the ToxTracker event and launch party during the SOT 2020 meeting in Anaheim. During this event we will launch new assays, software and the ToxTracker Academy. We will also update you on the latest developments around ToxTracker and its...
Toxys strengthens leadership team with appointment of CBO and COO positions
Leiden, The Netherlands. Jan. 21, 2020 - Today, Toxys announces the appointment of a Chief Business Officer (CBO) and a Chief Operating Officer (COO). Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative, high-fidelity in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties...
ToxTracker for regulatory applications
We are frequently asked whether ToxTracker data have ever been included in safety dossiers to the regulatory authorities. The answer is yes, but often this information is not publicly available. And in many cases we simply don’t know. But now there is an example available...
